Stereotaxis (NYSEAMERICAN:STXS – Get Free Report) is projected to announce its Q1 2026 results after the market closes on Tuesday, May 12th. Analysts expect the company to announce earnings of ($0.05) per share and revenue of $8.62 million for the quarter. Interested persons may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Tuesday, May 12, 2026 at 4:30 PM ET.
Stereotaxis (NYSEAMERICAN:STXS – Get Free Report) last posted its earnings results on Monday, March 9th. The company reported ($0.06) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.06). Stereotaxis had a negative return on equity of 291.99% and a negative net margin of 66.85%.The business had revenue of $8.64 million for the quarter, compared to analyst estimates of $9.24 million. On average, analysts expect Stereotaxis to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Stereotaxis Price Performance
Stereotaxis stock traded up $0.06 during mid-day trading on Tuesday, hitting $1.96. 70,041 shares of the company’s stock traded hands, compared to its average volume of 481,004. The firm has a 50 day simple moving average of $1.95 and a two-hundred day simple moving average of $2.30. Stereotaxis has a fifty-two week low of $1.74 and a fifty-two week high of $3.59. The stock has a market cap of $190.57 million, a price-to-earnings ratio of -7.78 and a beta of 1.34.
Institutional Trading of Stereotaxis
About Stereotaxis
Stereotaxis, Inc is a medical device company that develops and commercializes robotic magnetic navigation systems for use in electrophysiology procedures. Its core technology leverages precisely controlled magnetic fields to guide ultra-thin, magnetically enabled catheters through the vascular system, allowing physicians to perform complex cardiac ablation and diagnostic procedures with enhanced precision and stability. This platform aims to reduce procedure times and radiation exposure for both patients and clinical staff.
The company’s flagship offering, the Niobe Magnetic Navigation System, integrates with a variety of catheter types and electrophysiology mapping systems to support treatment of arrhythmias such as atrial fibrillation and ventricular tachycardia.
Read More
Receive News & Ratings for Stereotaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stereotaxis and related companies with MarketBeat.com's FREE daily email newsletter.
